Xeris Biopharma Holdings Financial Health
How is Xeris Biopharma Holdings's financial position?
Financial Health Score1/6
Financial Health Score 1/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: XERS's short term assets ($148.9M) exceed its short term liabilities ($68.6M).
Long Term Liabilities: XERS's short term assets ($148.9M) do not cover its long term liabilities ($179.4M).
Debt to Equity History and Analysis
Debt Level: XERS's net debt to equity ratio (81.9%) is considered high.
Reducing Debt: Insufficient data to determine if XERS's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: XERS has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if XERS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.